Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction
Document Type
Article
Publication Date
12-17-2021
Abstract
Importance: S100A12 is a calcium binding protein which is involved in inflammation and progression of atherosclerosis.
Objective: We sought to investigate the utility of S100A12 as a biomarker for the early diagnosis and prognostication of patients presenting with ST-segment elevation myocardial infarction (STEMI).
Design, Setting, and Participants: S100A12 was measured in 1023 patients presenting to the emergency department with acute chest pain between June 2012 and November 2015. An independent cohort of 398 patients enrolled at 3 different hospitals served as a validation cohort.
Main Outcomes and Measures: The primary clinical endpoint of interest was major adverse cardiac and cerebral events (MACCE) defined as a composite of all-cause death, MI, stroke, or hospitalization for heart failure.
Results: A total of 438/1023 patients (42.8%) in the diagnosis cohort were adjudicated as STEMI, among whom plasma S100A12 levels increased within 30 min and peaked 1–2 h after symptom onset. Compared with high-sensitivity cardiac troponin T and creatine kinase-MB isoenzyme, S100A12 more accurately identified STEMI, especially within the first 2 h after symptom onset (area under the curve 0.963 compared with 0.860 for hscTnT and 0.711 for CK-MB, both P < 0.05). These results were consistent in the 243-patient validation cohort. The 1-year rate of MACCE was greatest in patients in the highest peak S100A12 tertile, intermediate in the middle tertile and least in the lowest tertile (9.3 vs. 5.7 vs. 3.0% respectively, Ptrend = 0.0006). By multivariable analysis the peak plasma concentration of S100A12 was an independent predictor of MACCE within 1 year after STEMI (HR, 1.001, 95%CI, 1.000–1.002; P = 0.0104). Zhang et al. S100A12 as a STEMI Biomarker
Conclusions and Relevance: S100A12 rapidly identified patients with STEMI, more accurately than other cardiac biomarkers, especially within the first 2 h after symptom onset. The peak plasma S100A12 level was a strong predictor of 1-year prognosis after STEMI.
Recommended Citation
Zhang, Xiaolin; Cheng, Minghui; Gao, Naijing; Li, Yi; Yan, Chenghui; Tian, Xiaoxiang; Liu, Dan; Qiu, Miaohan; Wang, Xiaozeng; Luan, Bo; Deng, Jie; Wang, Shouli; Tian, Hongyan; Wang, Geng; Ma, Xin-Liang; Stone, Gregg W; and Han, Yaling, "Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction" (2021). Department of Emergency Medicine Faculty Papers. Paper 209.
https://jdc.jefferson.edu/emfp/209
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Corrigendum
Data_Sheet_1_Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction.docx (166 kB)
Supplemental Tables
PubMed ID
34977174
Language
English
Comments
This article has been corrected: see additional file, "Corrigendum".
This is the author's final published version in Frontiers in Cardiovascular Medicine, Volume 8, Dec. 2021, Article number 747511.
The published version is available at https://doi.org/10.3389/fcvm.2021.747511. Copyright © 2021 Zhang, Cheng, Gao, Li, Yan, Tian, Liu, Qiu, Wang, Luan, Deng, Wang, Tian, Wang, Ma, Stone and Han.